In the case of the global liothyronine market, patients with thyroid-related conditions must have regular thyroid function tests to check thyroid organ functionality and modify dosage based on the results. However, government lockdowns in various countries have made it difficult for patients to get regular tests and appointments. Furthermore, as a result of COVID-19, the governments of several countries, including India, the United States, Italy, and others, have imposed bans on non-urgent surgical treatments. As a result, patients who have been recommended thyroid surgery will have to wait until the ban is lifted.
The liothyronine drug is associated with side effects such as temporary hair loss during the first few days of treatment, which is most common in children.
Read more @ https://bit.ly/3mQNlk3
Source:
https://www.coherentmarketinsights.com/ongoing-insight/liothyronine-market-4159
